SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive
management team as Chief Regulatory Officer.
"We are very pleased to welcome Malcolm
Lloyd-Smith to the Neurocrine leadership team as our Chief
Regulatory Officer," said Kevin
Gorman, President and Chief Executive Officer of Neurocrine
Biosciences. "Malcolm brings a wealth of worldwide regulatory
experience and pharmaceutical development that is critical to
executing our regulatory strategy and facilitating the continued
growth in our preclinical and clinical development pipeline."
Prior to joining Neurocrine, Mr. Lloyd-Smith, age 59, served as
Senior Vice President, Regulatory Affairs, Quality and Clinical at
Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc in April
2014), a pharmaceutical company, since August 2012, prior to which he served as Senior
Vice President, Regulatory Affairs and Quality Assurance from
August 2008. Mr. Lloyd-Smith served
as Vice President and Head of Global Regulatory Affairs for Elan
Pharmaceuticals, Inc., a pharmaceutical company, from September 2003 to August
2008, after having served in the United Kingdom as its Vice President,
International Regulatory Affairs from March
2002 to August 2003.
Previously, Mr. Lloyd-Smith served in various positions of
increasing responsibility with DuPont Pharma Ltd. (acquired by
Bristol-Myers Squibb Company in 2001), serving as Vice President,
Worldwide Regulatory Affairs from 2001 to 2002, as Vice President,
Regulatory Affairs Europe from 1999 to 2001, and as Senior
Director, Regulatory Affairs Europe from 1994 to 1999. Mr.
Lloyd-Smith holds a B.Sc. in pharmacology from the University of
Leeds, and a M.Sc. in
pharmacological biochemistry from Hatfield Polytechnic.
Neurocrine also announced the grant of an inducement award to
Mr. Lloyd-Smith pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules in connection with his employment with Neurocrine. In
connection with the employment agreement, Mr. Lloyd-Smith was
granted an inducement award consisting of a stock option to
purchase 65,000 shares of Neurocrine common stock. The stock option
will vest over a period of four years, with 25% vesting on the
first anniversary of the grant date and the balance vesting each
month over the remaining three years. This award is subject to the
terms and conditions of Neurocrine's Inducement Plan. This award is
effective on October 1, 2014, the first day of the first calendar
month following the commencement of his employment with Neurocrine,
and has an exercise price of $15.45, which was the closing price of
Neurocrine's common stock on the NASDAQ Global Select Market on
that date. The award was granted as an inducement material to Mr.
Lloyd-Smith's employment pursuant to Rule 5635(b)(4) of the NASDAQ
Listing Rules.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial rights
to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.